Exosome treatment for multi-organ failure after aortic dissection surgery
Part of Heart & circulation, Injuries & trauma clinical trials.
This trial studies an infusion made from stem cells (called exosomes) to help people who develop failure in multiple organs after emergency surgery for a specific type of aortic tear. It aims to improve organ recovery and overall outcomes after the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had an emergency operation for acute type A aortic dissection with ascending aorta replacement and a triple-branch stent graft
- You are over 60 years old
- Before surgery, your breathing test was fairly good (PaO2/FiO2 is at least 400) and certain blood counts/liver markers were above set limits
- Before surgery, you had no dangerous low blood pressure that required medication and your brain function score was normal (Glasgow Coma Scale 15)
- If you are in the “multi-organ failure” group, you must have at least 2 failing organs and a SOFA score of 10 or higher
- You are not likely to qualify if you have life-threatening illness expected to last under 4 days, long-term steroid use in the past 6 months, visible blood-vessel involvement in the belly organs on CT scan, or severe pre-existing major organ disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the drug Sivelestat can protect organs like the heart, kidneys, and lungs after emergency surgery for a severe tear in the main artery from the heart (type A aortic dissection). If you are having this surgery, you may be able to join.
This trial tests new strategies for patients with a severe aortic tear (type A aortic dissection) that has caused blockages in blood vessels, leading to organ damage. It aims to find the best approach to restore blood flow and improve outcomes.
This trial tests if a therapy made from stem cells (called MSC-EVs) can help patients recover from severe liver failure after a liver transplant. It is for people who had a sudden worsening of chronic liver disease and needed a new liver.
This trial tests whether infusing stem cells (from a healthy donor) can help people with sudden liver failure that is not getting better with standard medicines and is not caused by viruses. It aims to improve liver function and possibly avoid the need for a transplant.
This clinical trial is testing a treatment made from stem cell exosomes — tiny particles that help cells communicate — given through an IV to people who have had a recent ischemic stroke caused by a blood clot. The study aims to see if it's safe and can help recovery when given within the first few days after a stroke.
This study tests whether exosomes from stem cells, given through the dialysis fluid, can help people on peritoneal dialysis whose dialysis isn't removing enough fluid. This may help reduce swelling and other symptoms of fluid overload.
Hear when a new Multiple Organ Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.